The Novartis Ophthalmology Case Awards 2018

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Announcing the 2018 Toxins Travel Awards for Post-Doctoral Fellows

This year we enjoyed a large number of very highy meritorious applications for our annual Toxins Travel Awards.[...].

متن کامل

Lumiracoxib (Novartis).

Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.

متن کامل

The Novartis Foundation

before — a hotbed of gene therapy research. It was a remarkable opportunity. Mulligan was offered one laboratory at the Children's Hospital to work on the basic science of viral vectors, and a second laboratory in a central Harvard building that will manufacture the vectors for use in human trials. Despite all these enticements, Mulligan did not agree to move — and leave a position at the White...

متن کامل

The Awards Program of the Association for Research in Vision and Ophthalmology.

F -L re rom the small informal research meetings which were held in New York in the late 1920's, the Association for Research in Vision and Ophthalmology (ARVO) has grown into the predominant scientific eye research organization of this country with more than two thousand members. Early in its development, the association began to honor distinguished contributions to vision and ophthalmology. I...

متن کامل

Fingolimod. Mitsubishi Pharma/Novartis.

Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: European Journal of Ophthalmology

سال: 2019

ISSN: 1120-6721,1724-6016

DOI: 10.1177/1120672119865624